학술논문

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
Document Type
Article
Source
In Blood Advances 23 January 2024 8(2):378-387
Subject
Lymphoid Neoplasia
Language
ISSN
2473-9529